further demonstrated that type I MET inhibitors, including capmatinib, induce compensatory PD-L1 elevation in HCC models, rendering tumors resistant to MET-targeted therapy but sensitized to PD-1 blockade. This evidence concerns the gene MET and hepatocellular carcinoma.